Filtered By:
Infectious Disease: Herpes
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 11557 results found since Jan 2013.
SOTYKTU < sup > TM < /sup > (Deucravacitinib 6-mg Tablets)- A New Agent for the Management of Adult Plaque Psoriasis
Skinmed. 2023 Aug 28;21(3):192-196. eCollection 2023.ABSTRACTSOTYKTUTM (deucravacitinib) is a newly approved oral agent for managing moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is a highly selective allosteric tyrosine kinase 2 inhibitor targeting dysregulated cytokine responses in psoriasis patients. Its efficacy was demonstrated in two randomized, placebo- and active comparator-controlled phase 3 trials, where a significantly higher proportion of patients, up to 58.4% (194/332), achieved lessening of symptoms at week 16. The recommended dosing reg...
Source: Skinmed - August 27, 2023 Category: Dermatology Authors: Aditya K Gupta Tong Wang Kimberly Vincent William Abramovits Source Type: research
